Most Read

The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing. The Garnet Valley site will focus on developing small molecule

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific

aGvHD is a leading cause of death following an allogeneic stem cell transplant due to the transplanted immune cells attacking the patient’s tissues. It results in a very

Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent

The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance

Designed to Current Good Manufacturing Practices (cGMP) specifications and certified by the Belgian Federal Agency for Medicines and Healthcare Products, the new €5m facility, adjacent to its headquarters

The two studies are projected to deliver a total of c.£9m in revenue, with most of the revenue being recognised in 2019. These contracts are in addition to

Hemlibra is now the only prophylactic treatment for people with haemophilia A with and without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at

Merck has announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to Delstrigo , a once-daily fixed-dose combination tablet of